NCT lookup

Key Inclusion Criteria:

For All Cohorts:

* Adult ≥ 18 years old.
* Metastatic disease not amenable to potentially curative surgery and with available archival tumor tissue or fresh tumor tissue biopsy.
* Presence of at least 1 measurable lesion assessed by CT and/or MRI according to RECIST 1.1.
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
* Adequate bone marrow and organ function per defined criteria in the protocol.
* Recovered from acute laboratory and clinical toxicities of prior anti cancer treatment to NCI CTCAE v5.0 grade ≤1 at time of screening, except alopecia and amenorrhea.

For Cohort A:

• First line metastatic colorectal adenocarcinoma.

For Cohort B:

• Second line metastatic colorectal adenocarcinoma that has progressed on prior line of chemotherapy administered for metastatic disease and which must include a fluoropyrimidine and oxaliplatin.

For Cohort C:

• Second line metastatic gastroesophageal adenocarcinoma that has progressed on prior line of chemotherapy administered for metastatic disease, and which must include a platinum agent and fluoropyrimidine doublet.

For Cohort D:

• Second or third line metastatic renal cell carcinoma with a clear cell component and has received one or two lines of treatment for metastatic disease that included an anti angiogenic agent for at least 4 weeks with radiologic progression on that treatment.

For subjects starting from Part 1a in Cohorts A and B:

* Serum hs CRP at screening ≥ 10 mg/L (per central laboratory assessment).
* Not requiring immediate initiation of anti cancer therapy per investigator's best judgement.

For subjects starting from Part 2 in Cohort C:

• Serum hs CRP at screening ≥ 10 mg/L (per central laboratory assessment).

Key Exclusion Criteria:

For All Cohorts:

* Currently receiving any of the prohibited medications or has contraindications as outlined in the 'Contraindications' to SOC regimen components.
* Symptomatic brain metastases or brain metastases that require directed therapy (such as focal radiotherapy or surgery).
* Suspected or proven immunocompromised state, or infections (as defined in the protocol).
* Conditions that have a high risk of clinically significant bleeding after administration of anti VEGF agents.
* Clinically significant, uncontrolled or recent (within last 6 months) cardiovascular disease.

For Cohort D:

* Concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYP3A4/5, and medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
* Impairment of GI function or GI disease that may significantly alter the absorption of cabozantinib.

Other protocol-defined inclusion/exclusion criteria may apply

• Los Angeles, California, United States
• St Louis, Missouri, United States
• Nashville, Tennessee, United States
• Melbourne, Victoria, Australia
• Brussels, Belgium
• Edegem, Belgium
• Leuven, Belgium
• Calgary, Alberta, Canada
• Toronto, Ontario, Canada
• Santiago, Santiago Metropolitan, Chile
• Brno, Czechia
• Frankfurt am Main, Hesse, Germany
• Dresden, Saxony, Germany
• Ulm, Germany
• Ramat Gan, Israel
• Tel Aviv, Israel
• Milan, MI, Italy
• Rozzano, MI, Italy
• Nagoya, Aichi-ken, Japan
• Kashiwa, Chiba, Japan
• Osaka, Osaka, Japan
• Sunto Gun, Shizuoka, Japan
• Bunkyo-ku, Tokyo, Japan
• Singapore, Singapore
• Seoul, South Korea
• L'Hospitalet de Llobregat, Barcelona, Spain
• Madrid, Spain
• Madrid, Spain
• Madrid, Spain
• Seville, Spain
• + 4 more on CT.gov